Mediterranean visceral leishmaniasis in HIV-negative adults: A retrospective analysis of 64 consecutive cases (1995-2001)

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 2, 2003, Pages 264-268

  Pagliano, Pasquale ^a   Rossi, Marco ^a   Rescigno, Carolina ^a   Altieri, Sergio ^a   Coppola, Maria Grazia ^a   Gramiccia, Marina ^b   Scalone, Aldo ^b   Gradoni, Luigi ^b   Faella, Francesco ^a  

^a AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Leishmania infantum; Liposomal amphotericin B; Meglumine antimoniate; Treatment; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; IMMUNOSUPPRESSIVE AGENT; MEGLUMINE ANTIMONATE;

ADULT; ARTICLE; BLOOD SMEAR; BONE MARROW BIOPSY; CLINICAL EXAMINATION; CLINICAL OBSERVATION; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG TOLERABILITY; ECG ABNORMALITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HEPATOSPLENOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LABORATORY TEST; LEISHMANIA INFANTUM; MAJOR CLINICAL STUDY; MALE; PANCYTOPENIA; PREGNANCY; RETROSPECTIVE STUDY; SOUTHERN EUROPE; SYMPTOMATOLOGY; TREATMENT FAILURE; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; CHI-SQUARE DISTRIBUTION; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; LEISHMANIASIS, VISCERAL; MALE; MEDITERRANEAN REGION; MIDDLE AGED; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; RETROSPECTIVE STUDIES;

EID: 0043029865     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg340     Document Type: Article

References (22)

1. Desjeux, P. (2001). The increase in risk factors for leishmaniasis worldwide. Transactions of the Royal Society of Tropical Medicine and Hygiene 95, 239-43.
2. Guerin, P. J., Olliaro, P., Sundar, S. et al. (2002). Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infectious Diseases 2, 494-501.
3. Gradoni, L., Pizzuti, R., Scalone, A. et al. (1996). Recrudescence of visceral leishmaniasis unrelated to HIV infection in the Campania region of Italy. Transactions of the Royal Society of Tropical Medicine and Hygiene 90, 234-5.
4. WHO. (1997). Leishmania/HIV co-infection. Epidemiological analysis of 692 retrospective cases. Weekly Epidemiological Record 72, 49-54.
5. Hernandez-Perez, J., Yebra-Bango, M., Jimenez-Martinez, E. et al. (1999). Visceral leishmaniasis (kala-azar) in solid organ transplantation: report of five cases and review. Clinical Infectious Diseases 29, 918-21.
6. Sundar, S., More, D. K., Singh, M. K. et al. (2000). Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clinical Infectious Diseases 31, 1104-6.
7. Herwaldt, B. L. & Berman, J. D. (1992). Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. American Journal of Tropical Medicine and Hygiene 46, 296-306.
8. Berman, J. D. (1988). Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Review of Infectious Diseases 10, 560-86.
9. Mishra, M., Biswas, U. K., Jha, A. M. et al. (1992). Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 340, 1256-7.
10. Mishra, M., Biswas, U. K., Jha, A. M. et al. (1994). Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 344, 1599-600.
11. Davidson, R. N., di Martino, L., Gradoni, L. et al. (1996). Shortcourse treatment of visceral leishmaniasis with liposomal amphotericin B (Ambisome). Clinical Infectious Diseases 22, 938-42.
12. Seaman, J., Boer, C., Wilkinson, R. et al. (1995). Liposomal amphotericin B (Ambisome) in the treatment of complicated kala-azar under field conditions. Clinical Infectious Diseases 21, 188-93.
13. Sundar, S., Jha, T. K., Thakur, C. P. et al. (2002). Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. American Journal of Tropical Medicine and Hygiene 66, 143-6.
14. Meyerhoff, A. (1999). U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of Visceral leishmaniasis. Clinical Infectious Diseases 28, 42-8.
15. Davidson, R. N. (1998). Practical guide for the treatment of leishmaniasis. Drugs 56, 1009-18.
16. WHO. (1990). World Health Organization Expert Committee: Control of the Leishmaniasis. WHO Technical Report Series, no. 793. WHO, Geneva.
17. Gramiccia, M., Gradoni, L., di Martino, L. et al. (1992). Two syntopic zymodemes of Leishmania infantum cause human and canine visceral leishmaniasis in the Naples area, Italy. Acta Tropica 50, 357-9.
18. Wegmann, T. G., Lin, H., Guilbert, L. J. et al. (1993). Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon? Immunology Today 14, 353-6.
19. Krishnan, L., Guilbert, L. J., Russel, A. S. et al. (1996). Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-γ response and increased production of T helper 2 cytokines. Journal of Immunology 156, 644-52.
20. Meinecke, C. K., Schottelius, J., Oskam, L. et al. (1999). Congenital transmission of visceral leishmaniasis (Kala Azar) from an asymptomatic mother to her child. Pediatrics 104, e65.
21. Murray, H. W. (2001). Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrobial Agents and Chemotherapy 45, 2185-97.
22. Boletis, J. N., Pefasis, A., Stathakis, C. et al. (1999). Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome). Clinical Infectious Diseases 28, 1308-9.